Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori

Clinical and Experimental Gastroenterology

Volumn 5, Issue 1, 2012, Pages 23-34

  Gisbert, Javier P ^a   Calvet, Xavier ^b  

^a Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^b HOSPITAL DE SABADELL   (Spain)

Author keywords

Clarithromycin; Concomitant therapy; Helicobacter pylori; Metronidazole; Non bismuth quadruple; Sequential therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; METRONIDAZOLE; NITROIMIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; ROXITHROMYCIN; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTENTION TO TREAT ANALYSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84859554392     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S25419     Document Type: Review

References (92)

1. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med. 2010;362(17):1597-1604.
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56(6):772-781.
3. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808-1825.
4. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998;13(1):1-12.
5. Coelho LG, Leon-Barua R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol. 2000;95(10):2688-2691.
6. Gisbert JP, Calvet X, Gomollon F, Mones J. Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference. Med Clin (Barc). 2005;125(8):301-316.
7. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12(4):275-278.
8. Sasaki M, Ogasawara N, Utsumi K, et al. Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin. J Clin Biochem Nutr. 2010;47(1):53-58.
9. Laine L, Fennerty MB, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials. Am J Gastroenterol. 2000;95(12):3393-3398.
10. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther. 2004;20(1):99-107.
11. Janssen MJ, Van Oijen AH, Verbeek AL, Jansen JB, De Boer WA. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment Pharmacol Ther. 2001;15(5):613-624.
12. Laheij RJ, Rossum LG, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther. 1999;13(7):857-864.
13. Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008; 68(6):725-736.
14. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta- analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14(5): 603-609.
15. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med. 2007;147(8): 553-562.
16. Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol. 2010;44(5):313-325.
17. Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet. 2007;370(9592):1010-1012.
18. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56(10):1353-1357.
19. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med. 2008;148(12):923-931.
20. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther. 2009;34(1):41-53.
21. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol. 2009;104(12):3069-3079; quiz 1080.
22. Caselli M, Zullo A, Maconi G, et al. "Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis. 2007;39(8):782-789.
23. Gisbert JP, Nyssen OP, McNicholl A, et al. Meta-analysis of sequential vs standard triple therapy for Helicobacter pylori eradication. Helicobacter. 2011;16(Suppl 1):131.
24. Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, et al. Clinical trial: clarithromycin vs levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2010;31(10):1077-1084.
25. Gao XZ, Qiao XL, Song WC, Wang XF, Liu F. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. World J Gastroenterol. 2010;16(34):4357-4362.
26. Paoluzi OA, Visconti E, Andrei F, et al. Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol. 2010;44(4):261-266.
27. Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut. 2010;59(11): 1465-1470.
28. Gisbert JP. Sequential or concomitant therapy for Helicobacter pylori eradication? J Clin Gastroenterol. 2010;44:658-659.
29. Vakil N. Helicobacter pylori treatment: is sequential or quadruple therapy the answer? Rev Gastroenterol Disord. 2008;8(2):77-82.
30. Graham DY, Lu H. Is there a role for sequential in sequential anti-H. pylori therapy? Gastroenterology. 2006;130(6):1930-1931; author reply 1931.
31. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther. 2011;34(6):604-617.
32. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5(6):321-331.
33. Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/metronidazole/ omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter. 1998;3(1):54-58.
34. Okada M, Oki K, Shirotani T, et al. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omepra- zole on the cure rate. J Gastroenterol. 1998;33(5):640-645.
35. Perri F, Clemente R, Festa V, et al. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol. 1998;30(2):146-150.
36. Maconi G, Parente F, Russo A, Vago L, Imbesi V, Bianchi Porro G. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol. 2001;96(2):359-366.
37. Lai YC, Yang JC, Huang SH. Pre-treatment urea breath test results predict the efficacy of Helicobacter pylori eradication therapy in patients with active duodenal ulcers. World J Gastroenterol. 2004;10(7):991-994.
38. Moshkowitz M, Konikoff FM, Peled Y, et al. High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut. 1995;36(6):845-847.
39. Luther J, Chey WD. Sequential therapy for Helicobacter pylori: a two for one deal that's worth the extra effort? Gastroenterology. 2009;136(2): 720-722.
40. Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents. 2002;19(1):67-70.
41. Paulsen IT, Brown MH, Skurray RA. Proton-dependent multidrug efflux systems. Microbiol Rev. 1996;60(4):575-608.
42. Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother. 2003;51(1):9-11.
43. Roberts MC. Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics. Mol Biotechnol. 2004;28(1): 47-62.
44. De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med. 2006;144(2):94-100.
45. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007;146(8):556-563.
46. Summaries for patients. Sequential therapy versus standard triple- drug therapy for Helicobacter pylori eradication. Ann Intern Med. 2007;146(8):I20.
47. Calvet X, Tito L, Comet R, Garcia N, Campo R, Brullet E. Four-day, twice daily, quadruple therapy with amoxicillin, clarithromycin, tinida-zole and omeprazole to cure Helicobacter pylori infection: a pilot study. Helicobacter. 2000;5(1):52-56.
48. Catalano F, Branciforte G, Catanzaro R, Cipolla R, Bentivegna C, Brogna A. Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. Aliment Pharmacol Ther. 2000;14(10): 1329-1334.
49. Chan KL, Zhou H, Ng DK, Tam PK. A prospective study of a one- week non-bismuth quadruple therapy for childhood Helicobacter pylori infection. J Pediatr Surg. 2001;36(7):1008-1011.
50. Molina-Infante J, Pazos-Pacheco C, Perez-Gallardo B, et al. Efficacy of 10-day non-bismuth quadruple "concomitant" regimen as first-line therapy for Helicobacter pylori infection in a setting with high rates of clarithromycin and dual clarithromycin and metronidazole resistance. Helicobacter. 2011;16(Suppl 1):133.
51. Nagahara A, Miwa H, Ogawa K, et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter. 2000;5(2):88-93.
52. Nagahara A, Miwa H, Yamada T, Kurosawa A, Ohkura R, Sato N. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther. 2001;15(3):417-421.
53. Neville PM, Everett S, Langworthy H, et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther. 1999;13(4):497-501.
54. Okada M, Nishimura H, Kawashima M, et al. A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment Pharmacol Ther. 1999;13(6):769-774.
55. Treiber G, Wittig J, Ammon S, Walker S, van Doorn LJ, Klotz U. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med. 2002;162(2): 153-160.
56. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with 4 drugs are equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol. 2010;8:36-41.
57. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011;378(9790):507-514.
58. Kongchayanun C, Mahachai V, Pornthisarn B, Amornsawadwattana S, Vilaichone RK. Efficacy of 10-day and 5-day concomitant therapy for Helicobacter pylori eradication in Thai patients with non ulcer dyspepsia. Gastroenterology. 2011;140(Suppl 1):879.
59. Kim SY, Lee SW, Kwon BS, et al. Comparative study of Helicobacter pylori eradication rates of 5-day quadruple "Concomitant" therapy and 7-day standard triple therapy. Gastroenterology. 2011; 140(Suppl 1):878.
60. Toros AB, Ince AT, Kesici B, Saglam M, Polat Z, Uygun A. A new modified concomitant therapy for Helicobacter pylori eradication in Turkey. Helicobacter. 2011;16(3):225-228.
61. Kwon BS, Park EB, Lee DH, et al. Effectiveness of 5-day and 7-day quadruple "concomitant" therapy regimen for Helicobacter pylori infection in Korea. Helicobacter. 2011;16(Suppl 1):135.
62. Moon B, Lim H, Lee S, Han K, Chung J, Lee Y. Efficacy of concomitant nonbithmuth-based quadruple therapy as first-line treatment for eradication of Helicobacter pylori. Helicobacter. 2011;16(Suppl 1):131.
63. Choi C, Lee D, Chon I, et al. Concomitant therapy was more effective than ppi-base triple therapy in Korea: a preliminary report. Helicobacter. 2011;16(Suppl 1):136.
64. Gumurdulu Y, Serin E, Ozer B, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol. 2004;10(5):668-671.
65. Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter. 2002;7(5):306-309.
66. Vakil N. H. pylori treatment: new wine in old bottles? Am J Gastroenterol. 2009;104(1):26-30.
67. Megraud F. H. Pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53(9):1374-1384.
68. Megraud F. Helicobacter pylori and antibiotic resistance. Gut. 2007; 56(11):1502.
69. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26(3):343-357.
70. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002;16(6):1047-1057.
71. Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter. 2005;10(5):363-372.
72. Vakil N, Vaira D. Sequential therapy for Helicobacter pylori: time to consider making the switch? JAMA. 2008;300(11):1346-1347.
73. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999;13(8):1047-1055.
74. Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther. 2003; 17(5):719-726.
75. Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, et al. Non-bismuth quadruple "concomitant" therapy versus standard triple therapy for clarithromycin-susceptible H. pylori and versus quadruple "sequential" therapy for clarithromycin-resistant H. pylori. Helicobacter. 2011;16(Suppl 1):135.
76. O'Morain CA, O'Connor JP. Is sequential therapy superior to standard triple therapy for the treatment of Helicobacter pylori infection? Nat Clin Pract Gastroenterol Hepatol. 2009;6(1):8-9.
77. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(2):109-118.
78. Calvet X, Gene E, Lopez T, Gisbert JP. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. Aliment Pharmacol Ther. 2001;15(7): 1067-1076.
79. de Boer WA, Kuipers EJ, Kusters JG. Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use? Dig Liver Dis. 2004;36(5):311-314.
80. Liou JM, Lin JT, Chang CY, et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut. 2010;59(5):572-578.
81. Peitz U, Sulliga M, Wolle K, et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther. 2002;16(2):315-324.
82. Beales IL. Efficacy of Helicobacter pylori eradication therapies: a single centre observational study. BMC Gastroenterol. 2001;1:7.
83. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006;23(1):35-44.
84. Gisbert JP, Bermejo F, Castro-Fernandez M, et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol. 2008;103(1):71-76.
85. Gisbert JP, Castro-Fernandez M, Bermejo F, et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol. 2006;101(2):243-247.
86. Zullo A, De Francesco V, Hassan C. Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study. Therapy. 2006;3:251-254.
87. Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin- based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis. 2007;39(11):1001-1005.
88. Gisbert JP, Vinagre-Rodriguez G, Marin AC, Molina-Infante J. Second-line rescue triple therapy with levofloxacin after quadruple nonbismuth "sequential" or "concomitant" treatment failure. Helicobacter. 2011;16(Suppl 1):135.
89. Zullo A, Hassan C, Morini S, et al. Sequential therapy for H. pylori: an 'aberrant' therapy ready for general use. Dig Liver Dis. 2004;36(12):852-853; author reply 853.
90. Scaccianoce G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol. 2006;20(2):113-117.
91. Shehada S, Srugo I, Shaoul R. Failure of sequential therapy to eradicate Helicobacter pylori in previously treated subjects. Helicobacter. 2007;12(6):645-647.
92. Gisbert JP. Rescue therapy after Helicobacter pylori eradication failure. Gastroenterol Hepatol. 2011;34(2):89-99.